Logo image of CLOE

CLOVER LEAF CAPITAL CORP -A (CLOE) Stock Fundamental Analysis

NASDAQ:CLOE - Nasdaq - US18915E1055 - Common Stock - Currency: USD

11.675  -0.4 (-3.35%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to CLOE. CLOE was compared to 0 industry peers in the Unkown industry. CLOE may be in some trouble as it scores bad on both profitability and health. CLOE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLOE has reported negative net income.
In the past year CLOE has reported a negative cash flow from operations.
CLOE Yearly Net Income VS EBIT VS OCF VS FCFCLOE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -500K -1M -1.5M

1.2 Ratios

Industry RankSector Rank
ROA -10.13%
ROE -60.96%
ROIC N/A
ROA(3y)-2.42%
ROA(5y)N/A
ROE(3y)-6.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLOE Yearly ROA, ROE, ROICCLOE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -5 -10 -15

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLOE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLOE Yearly Profit, Operating, Gross MarginsCLOE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, CLOE has less shares outstanding
The debt/assets ratio for CLOE is higher compared to a year ago.
CLOE Yearly Shares OutstandingCLOE Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M
CLOE Yearly Total Debt VS Total AssetsCLOE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of 1.05, we must say that CLOE is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 2.15 is on the high side and indicates that CLOE has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 2.15
Debt/FCF N/A
Altman-Z 1.05
ROIC/WACCN/A
WACCN/A
CLOE Yearly LT Debt VS Equity VS FCFCLOE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

CLOE has a Current Ratio of 0.02. This is a bad value and indicates that CLOE is not financially healthy enough and could expect problems in meeting its short term obligations.
CLOE has a Quick Ratio of 0.02. This is a bad value and indicates that CLOE is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
CLOE Yearly Current Assets VS Current LiabilitesCLOE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CLOE have decreased strongly by -248.93% in the last year.
EPS 1Y (TTM)-248.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLOE Yearly Revenue VS EstimatesCLOE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023
CLOE Yearly EPS VS EstimatesCLOE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLOE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLOE Price Earnings VS Forward Price EarningsCLOE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLOE Per share dataCLOE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CLOE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLOVER LEAF CAPITAL CORP -A

NASDAQ:CLOE (9/3/2024, 8:00:00 PM)

11.675

-0.4 (-3.35%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-14 2024-08-14
Earnings (Next)11-11 2024-11-11
Inst Owners7.44%
Inst Owner Change0%
Ins Owners11.53%
Ins Owner Change0%
Market Cap57.91M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 26.76
P/tB 26.76
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.13%
ROE -60.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.42%
ROA(5y)N/A
ROE(3y)-6.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z 1.05
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-248.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.96%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.53%
OCF growth 3YN/A
OCF growth 5YN/A